{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:12:04Z","timestamp":1777281124374,"version":"3.51.4"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01784-5","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:24:50Z","timestamp":1777278290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Drug Conjugates Reshape the Landscape of Cancer Therapy: Evolution, Challenges and Future Perspectives from the Concept of \u201cMagic Bullet\u201d to Clinical Application"],"prefix":"10.1007","volume":"28","author":[{"given":"Yixuan","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"3","key":"1784_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1784_CR2","doi-asserted-by":"publisher","unstructured":"Gliwska E, Guzek D, Przekop Z, Sobocki J, G\u0142\u0105bska D. Quality of Life of Cancer Patients Receiving Enteral Nutrition: A Systematic Review of Randomized Controlled Trials. Nutrients. 2021;13(12). https:\/\/doi.org\/10.3390\/nu13124551.","DOI":"10.3390\/nu13124551"},{"issue":"1","key":"1784_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduct Target Ther. 2024;9(1):175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1021\/acs.bioconjchem.5b00399","volume":"26","author":"MR Gordon","year":"2015","unstructured":"Gordon MR, Canakci M, Li L, Zhuang J, Osborne B, Thayumanavan S. Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. Bioconjug Chem. 2015;26(11):2198\u2013215. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5b00399.","journal-title":"Bioconjug Chem"},{"issue":"15","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1002\/anie.201307628","volume":"53","author":"RV Chari","year":"2014","unstructured":"Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl. 2014;53(15):3796\u2013827. https:\/\/doi.org\/10.1002\/anie.201307628.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"1784_CR6","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1039\/d5nh00325c","volume":"10","author":"L Tian","year":"2025","unstructured":"Tian L, Ma P, Zhuang W, Xu Y, Pang L, Guo K, et al. A transferrin-targeted nanoplatform for MRI-guided visualization and potent suppression of tumors and pulmonary metastatic lesions. Nanoscale Horiz. 2025;10(10):2422\u201333. https:\/\/doi.org\/10.1039\/d5nh00325c.","journal-title":"Nanoscale Horiz"},{"key":"1784_CR7","doi-asserted-by":"publisher","unstructured":"Wilson EM, Eskander RN, Binder PS. Recent Therapeutic Advances in Gynecologic Oncology: A Review. Cancers (Basel). 2024;16(4). https:\/\/doi.org\/10.3390\/cancers16040770.","DOI":"10.3390\/cancers16040770"},{"issue":"1","key":"1784_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s11671-025-04303-w","volume":"20","author":"T Dixit","year":"2025","unstructured":"Dixit T, Aswini A, Nikam H, Vaidya A, Ravindran S. Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates. Discov Nano. 2025;20(1):139. https:\/\/doi.org\/10.1186\/s11671-025-04303-w.","journal-title":"Discov Nano"},{"issue":"1","key":"1784_CR9","doi-asserted-by":"publisher","first-page":"1914885","DOI":"10.1080\/19420862.2021.1914885","volume":"13","author":"MJ Ko","year":"2021","unstructured":"Ko MJ, Song D, Kim J, Kim JY, Eom J, Sung B, et al. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability. MAbs. 2021;13(1):1914885. https:\/\/doi.org\/10.1080\/19420862.2021.1914885.","journal-title":"MAbs"},{"key":"1784_CR10","doi-asserted-by":"publisher","unstructured":"Baah S, Laws M, Rahman KM. Antibody-Drug Conjugates-A Tutorial Review. Molecules. 2021;26(10). https:\/\/doi.org\/10.3390\/molecules26102943.","DOI":"10.3390\/molecules26102943"},{"key":"1784_CR11","doi-asserted-by":"publisher","unstructured":"Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers (Basel). 2023;15(6). https:\/\/doi.org\/10.3390\/cancers15061845.","DOI":"10.3390\/cancers15061845"},{"key":"1784_CR12","doi-asserted-by":"publisher","first-page":"1328145","DOI":"10.3389\/fimmu.2024.1328145","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Cheng Y, Mu Y, Zhang Z, Tian D, Liu Y, et al. Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview. Front Immunol. 2024;15:1328145. https:\/\/doi.org\/10.3389\/fimmu.2024.1328145.","journal-title":"Front Immunol"},{"key":"1784_CR13","doi-asserted-by":"publisher","first-page":"718590","DOI":"10.3389\/fonc.2021.718590","volume":"11","author":"S Parakh","year":"2021","unstructured":"Parakh S, Nicolazzo J, Scott AM, Gan HK. Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them? Front Oncol. 2021;11:718590. https:\/\/doi.org\/10.3389\/fonc.2021.718590.","journal-title":"Front Oncol"},{"key":"1784_CR14","doi-asserted-by":"publisher","unstructured":"Johan AN, Li Y. Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy. Pharmaceuticals (Basel). 2022;15(6). https:\/\/doi.org\/10.3390\/ph15060655.","DOI":"10.3390\/ph15060655"},{"issue":"6","key":"1784_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A. Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473\u201380. https:\/\/doi.org\/10.1038\/nrc2394.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1784_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/bjc.1983.4","volume":"47","author":"CH Ford","year":"1983","unstructured":"Ford CH, Newman CE, Johnson JR, Woodhouse CS, Reeder TA, Rowland GF, et al. Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer. Br J Cancer. 1983;47(1):35\u201342. https:\/\/doi.org\/10.1038\/bjc.1983.4.","journal-title":"Br J Cancer"},{"issue":"5517","key":"1784_CR17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137. https:\/\/doi.org\/10.1038\/256495a0.","journal-title":"Nature"},{"issue":"5","key":"1784_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1784_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43556-022-00100-4","volume":"3","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang G, Lu H, Li H, Tang M, Tong A. Development of therapeutic antibodies for the treatment of diseases. Mol Biomed. 2022;3(1):35. https:\/\/doi.org\/10.1186\/s43556-022-00100-4.","journal-title":"Mol Biomed"},{"key":"1784_CR20","doi-asserted-by":"publisher","unstructured":"Yasui H, Idogawa M, Ishida T, Imai K. Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders. Cells. 2025;15(1). https:\/\/doi.org\/10.3390\/cells15010046.","DOI":"10.3390\/cells15010046"},{"issue":"1","key":"1784_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.Ccr-13-0541","volume":"20","author":"I Krop","year":"2014","unstructured":"Krop I, Winer EP. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Clin Cancer Res. 2014;20(1):15\u201320. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0541.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1784_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1158\/1078-0432.Ccr-12-0290","volume":"19","author":"C Deng","year":"2013","unstructured":"Deng C, Pan B, O\u2019Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22\u2013. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-0290. \u20097.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"1784_CR23","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1158\/1078-0432.Ccr-20-4557","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan P, Osgood CL, Singh H, Chiu HJ, Ricks TK, Chiu Yuen Chow E, et al. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clin Cancer Res. 2021;27(16):4478\u201385. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4557.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1784_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","volume":"10","author":"P Zhao","year":"2020","unstructured":"Zhao P, Zhang Y, Li W, Jeanty C, Xiang G, Dong Y. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm Sin B. 2020;10(9):1589\u2013600. https:\/\/doi.org\/10.1016\/j.apsb.2020.04.012.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"1784_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, Mo C, Zhao X, Liu G, et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51. https:\/\/doi.org\/10.1186\/s13045-025-01704-3.","journal-title":"J Hematol Oncol"},{"key":"1784_CR26","doi-asserted-by":"publisher","unstructured":"Li SC, Luo J, Lee KL. Cancer Niche as a Garbage Disposal Machine: Implications of TCM-Mediated Balance of Body-Disease for Treatment of Cancer. Online J Complement Altern Med. 2019;1(3). https:\/\/doi.org\/10.33552\/ojcam.2019.01.000514.","DOI":"10.33552\/ojcam.2019.01.000514"},{"issue":"1","key":"1784_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3892\/mmr.2015.3441","volume":"12","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Gou LT, Guo ZH, Liu HR, Wang JM, Zhou SX, et al. Fully human HER2\/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer. Mol Med Rep. 2015;12(1):147\u201354. https:\/\/doi.org\/10.3892\/mmr.2015.3441.","journal-title":"Mol Med Rep"},{"issue":"10","key":"1784_CR28","doi-asserted-by":"publisher","first-page":"e0334513","DOI":"10.1371\/journal.pone.0334513","volume":"20","author":"M Rao","year":"2025","unstructured":"Rao M, Wu L, Chen H, Wu X, Wang H, Chen Y, et al. Hematological toxicity of anti-tumor antibody-drug conjugates: A retrospective pharmacovigilance study using the FDA adverse event reporting system. PLoS ONE. 2025;20(10):e0334513. https:\/\/doi.org\/10.1371\/journal.pone.0334513.","journal-title":"PLoS ONE"},{"issue":"8","key":"1784_CR29","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1021\/acs.bioconjchem.1c00314","volume":"32","author":"C Ou","year":"2021","unstructured":"Ou C, Li C, Zhang R, Yang Q, Zong G, Dai Y, et al. One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. Bioconjug Chem. 2021;32(8):1888\u201397. https:\/\/doi.org\/10.1021\/acs.bioconjchem.1c00314.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"1784_CR30","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1080\/19420862.2019.1624127","volume":"11","author":"M Cao","year":"2019","unstructured":"Cao M, De Mel N, Jiao Y, Howard J, Parthemore C, Korman S, et al. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis. MAbs. 2019;11(6):1064\u201376. https:\/\/doi.org\/10.1080\/19420862.2019.1624127.","journal-title":"MAbs"},{"key":"1784_CR31","doi-asserted-by":"publisher","unstructured":"Yasunaga M, Manabe S, Tsuji A, Furuta M, Ogata K, Koga Y, et al. Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. Bioeng (Basel). 2017;4(3). https:\/\/doi.org\/10.3390\/bioengineering4030078.","DOI":"10.3390\/bioengineering4030078"},{"issue":"7","key":"1784_CR32","doi-asserted-by":"publisher","first-page":"e0131177","DOI":"10.1371\/journal.pone.0131177","volume":"10","author":"RR Beerli","year":"2015","unstructured":"Beerli RR, Hell T, Merkel AS, Grawunder U. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. PLoS ONE. 2015;10(7):e0131177. https:\/\/doi.org\/10.1371\/journal.pone.0131177.","journal-title":"PLoS ONE"},{"key":"1784_CR33","doi-asserted-by":"publisher","unstructured":"Cahuzac H, Devel L. Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices. Pharmaceuticals (Basel). 2020;13(12). https:\/\/doi.org\/10.3390\/ph13120462.","DOI":"10.3390\/ph13120462"},{"key":"1784_CR34","doi-asserted-by":"publisher","first-page":"1097983","DOI":"10.3389\/fonc.2023.1097983","volume":"13","author":"T Yang","year":"2023","unstructured":"Yang T, Kang L, Li D, Song Y. Immunotherapy for HER-2 positive breast cancer. Front Oncol. 2023;13:1097983. https:\/\/doi.org\/10.3389\/fonc.2023.1097983.","journal-title":"Front Oncol"},{"key":"1784_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/cdr.2024.180","volume":"8","author":"\u00c9A Larose","year":"2025","unstructured":"Larose \u00c9A, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. Cancer Drug Resist. 2025;8:11. https:\/\/doi.org\/10.20517\/cdr.2024.180.","journal-title":"Cancer Drug Resist"},{"key":"1784_CR36","doi-asserted-by":"publisher","unstructured":"Ettorre VM, Palmieri L, Clemente V, Santin AD. HER2\/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma. Cells. 2025;14(16). https:\/\/doi.org\/10.3390\/cells14161282.","DOI":"10.3390\/cells14161282"},{"key":"1784_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","volume":"7","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24. https:\/\/doi.org\/10.1186\/s40364-019-0175-x.","journal-title":"Biomark Res"},{"key":"1784_CR38","doi-asserted-by":"publisher","unstructured":"Alanazi AS, Alanazi AA, Alanizi A, Babalghaith R, Alotaibi R, Alnuhait M, et al. Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center. Curr Oncol. 2025;32(10). https:\/\/doi.org\/10.3390\/curroncol32100575.","DOI":"10.3390\/curroncol32100575"},{"key":"1784_CR39","doi-asserted-by":"publisher","unstructured":"Policastro B, Nissen N, Alves CL. Deciphering Breast Tumor Heterogeneity Through Patient-Derived Organoids and Circulating Tumor Cells. J Pers Med. 2025;15(7). https:\/\/doi.org\/10.3390\/jpm15070271.","DOI":"10.3390\/jpm15070271"},{"key":"1784_CR40","doi-asserted-by":"publisher","unstructured":"Healey GD, Frostell A, Fagge T, Gonzalez D, Conlan RS. A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development. Antibodies (Basel). 2019;8(1). https:\/\/doi.org\/10.3390\/antib8010007.","DOI":"10.3390\/antib8010007"},{"key":"1784_CR41","doi-asserted-by":"publisher","first-page":"175883592095372","DOI":"10.1177\/1758835920953729","volume":"12","author":"WL Chan","year":"2020","unstructured":"Chan WL, Lam TC, Lam KO, Luk MY, Kai-Cheong RN, Kwong LD. Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review. Ther Adv Med Oncol. 2020;12:1758835920953729. https:\/\/doi.org\/10.1177\/1758835920953729.","journal-title":"Ther Adv Med Oncol"},{"key":"1784_CR42","doi-asserted-by":"publisher","unstructured":"Dumitru AV, \u021a\u0103poi DA, Halcu G, Munteanu O, Dumitrascu DI, Ceau\u0219u MC, et al. The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment. Cells. 2023;12(13). https:\/\/doi.org\/10.3390\/cells12131783.","DOI":"10.3390\/cells12131783"},{"key":"1784_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bbacli.2017.01.001","volume":"7","author":"KE Lukong","year":"2017","unstructured":"Lukong KE. Understanding breast cancer - The long and winding road. BBA Clin. 2017;7:64\u201377. https:\/\/doi.org\/10.1016\/j.bbacli.2017.01.001.","journal-title":"BBA Clin"},{"issue":"1","key":"1784_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdu486","volume":"26","author":"IE Krop","year":"2015","unstructured":"Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdu486.","journal-title":"Ann Oncol"},{"issue":"23","key":"1784_CR45","doi-asserted-by":"publisher","first-page":"e2102414","DOI":"10.1002\/advs.202102414","volume":"8","author":"SH Shin","year":"2021","unstructured":"Shin SH, Park YH, Park SS, Ju EJ, Park J, Ko EJ, et al. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Adv Sci (Weinh). 2021;8(23):e2102414. https:\/\/doi.org\/10.1002\/advs.202102414.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"1784_CR46","doi-asserted-by":"publisher","first-page":"7088","DOI":"10.3390\/curroncol31110522","volume":"31","author":"S Fasih","year":"2024","unstructured":"Fasih S, Welch S, Lohmann AE, Antibody-Drug Conjugates. A Start of a New Era in Gynecological Cancers. Curr Oncol. 2024;31(11):7088\u2013106. https:\/\/doi.org\/10.3390\/curroncol31110522.","journal-title":"Curr Oncol"},{"key":"1784_CR47","doi-asserted-by":"publisher","unstructured":"McGranahan TM, Bonm AV, Specht JM, Venur V, Lo SS. Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer. Cancers (Basel). 2022;14(20). https:\/\/doi.org\/10.3390\/cancers14205136.","DOI":"10.3390\/cancers14205136"},{"issue":"3","key":"1784_CR48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173\u201385. https:\/\/doi.org\/10.1248\/cpb.c18-00744.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1784_CR49","doi-asserted-by":"publisher","unstructured":"Mihaylova R, Momekova D, Elincheva V, Momekov G. Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy. Pharmaceuticals (Basel). 2024;17(12). https:\/\/doi.org\/10.3390\/ph17121701.","DOI":"10.3390\/ph17121701"},{"issue":"10","key":"1784_CR50","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3348\/kjr.2025.0416","volume":"26","author":"S Eid","year":"2025","unstructured":"Eid S, Al-Yousef AS, Kim KW, Yoon S, Nawfal R, Bellmunt J, et al. State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer. Korean J Radiol. 2025;26(10):959\u201372. https:\/\/doi.org\/10.3348\/kjr.2025.0416.","journal-title":"Korean J Radiol"},{"key":"1784_CR51","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/bctt.S385341","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu J, Sun X, Du Q, Yao J, Dai M, Cheng Q, et al. Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis. Breast Cancer (Dove Med Press). 2022;14:491\u2013504. https:\/\/doi.org\/10.2147\/bctt.S385341.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"1","key":"1784_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1784_CR53","doi-asserted-by":"publisher","first-page":"213430","DOI":"10.1016\/j.bioadv.2023.213430","volume":"150","author":"A Gonsalves","year":"2023","unstructured":"Gonsalves A, Sorkhdini P, Bazinet J, Ghumman M, Dhamecha D, Zhou Y, et al. Development and characterization of lung surfactant-coated polymer nanoparticles for pulmonary drug delivery. Biomater Adv. 2023;150:213430. https:\/\/doi.org\/10.1016\/j.bioadv.2023.213430.","journal-title":"Biomater Adv"},{"issue":"3","key":"1784_CR54","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s12325-022-02365-1","volume":"40","author":"M Huang","year":"2023","unstructured":"Huang M, P AF, Haiderali A, Xue W, Yang C, Pan W, et al. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States. Adv Ther. 2023;40(3):1153\u201370. https:\/\/doi.org\/10.1007\/s12325-022-02365-1.","journal-title":"Adv Ther"},{"key":"1784_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/pgpm.S55339","volume":"7","author":"TA Yap","year":"2014","unstructured":"Yap TA, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med. 2014;7:285\u201395. https:\/\/doi.org\/10.2147\/pgpm.S55339.","journal-title":"Pharmgenomics Pers Med"},{"key":"1784_CR56","doi-asserted-by":"publisher","unstructured":"Br\u00f6ckelmann PJ, B\u00f6ll B. Moving things forward in Hodgkin lymphoma. F1000Res. 2018;7. https:\/\/doi.org\/10.12688\/f1000research.16077.1.","DOI":"10.12688\/f1000research.16077.1"},{"key":"1784_CR57","doi-asserted-by":"publisher","first-page":"929012","DOI":"10.3389\/fonc.2022.929012","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Xing Z, Mi L, Li Z, Zhu J, Wei T, et al. Novel Agents For Relapsed and Refractory Classical Hodgkin Lymphoma: A Review. Front Oncol. 2022;12:929012. https:\/\/doi.org\/10.3389\/fonc.2022.929012.","journal-title":"Front Oncol"},{"issue":"1","key":"1784_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-024-07333-7","volume":"207","author":"T Takano","year":"2024","unstructured":"Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, et al. Long-term outcomes of neoadjuvant trastuzumab emtansine\u2009+\u2009pertuzumab (T-DM1\u2009+\u2009P) and docetaxel\u2009+\u2009carboplatin\u2009+\u2009trastuzumab\u2009+\u2009pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast Cancer Res Treat. 2024;207(1):33\u201348. https:\/\/doi.org\/10.1007\/s10549-024-07333-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1784_CR59","doi-asserted-by":"publisher","first-page":"e079603","DOI":"10.1136\/bmj-2024-079603","volume":"387","author":"M He","year":"2024","unstructured":"He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, et al. Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial. BMJ. 2024;387:e079603. https:\/\/doi.org\/10.1136\/bmj-2024-079603.","journal-title":"BMJ"},{"issue":"1","key":"1784_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","volume":"44","author":"DY Ruan","year":"2024","unstructured":"Ruan DY, Wu HX, Meng Q, Xu RH. Development of antibody-drug conjugates in cancer: Overview and prospects. Cancer Commun (Lond). 2024;44(1):3\u201322. https:\/\/doi.org\/10.1002\/cac2.12517.","journal-title":"Cancer Commun (Lond)"},{"issue":"23","key":"1784_CR61","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, et al. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med. 2025;393(23):2324\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2511648.","journal-title":"N Engl J Med"},{"issue":"2","key":"1784_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.20892\/j.issn.2095-3941.2024.0486","volume":"22","author":"Z Shi","year":"2025","unstructured":"Shi Z, Lu Y, Zhao Q, Wang Y, Qiu P. Antibody-drug conjugates in breast cancer: advances and prospects. Cancer Biol Med. 2025;22(2):83\u201392. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0486.","journal-title":"Cancer Biol Med"},{"issue":"10","key":"1784_CR63","doi-asserted-by":"publisher","first-page":"689","DOI":"10.20892\/j.issn.2095-3941.2023.0286","volume":"20","author":"LJ Dai","year":"2023","unstructured":"Dai LJ, Li YW, Ma D, Shao ZM, Jiang YZ. Next-generation antibody-drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer. Cancer Biol Med. 2023;20(10):689\u201394. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0286.","journal-title":"Cancer Biol Med"},{"issue":"2","key":"1784_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","volume":"37","author":"N Harbeck","year":"2026","unstructured":"Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol. 2026;37(2):166\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.019.","journal-title":"Ann Oncol"},{"key":"1784_CR65","doi-asserted-by":"publisher","first-page":"481","DOI":"10.18632\/oncotarget.28741","volume":"16","author":"EA Karam","year":"2025","unstructured":"Karam EA, C\u00e9line YC, Prince G, Attieh F, Kourie HR, Kattan J, et al. Optimizing enfortumab vedotin plus pembrolizumab therapy. Oncotarget. 2025;16:481\u201394. https:\/\/doi.org\/10.18632\/oncotarget.28741.","journal-title":"Oncotarget"},{"issue":"5","key":"1784_CR66","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/bjc.2012.335","volume":"107","author":"G Minuti","year":"2012","unstructured":"Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O\u2019Brien T, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 2012;107(5):793\u20139. https:\/\/doi.org\/10.1038\/bjc.2012.335.","journal-title":"Br J Cancer"},{"key":"1784_CR67","doi-asserted-by":"publisher","unstructured":"Gu A, Li J, Li MY, Liu Y. Patient-derived xenograft model in cancer: establishment and applications. MedComm (2020). 2025;6(2):e70059. https:\/\/doi.org\/10.1002\/mco2.70059","DOI":"10.1002\/mco2.70059"},{"issue":"9","key":"1784_CR68","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1097\/js9.0000000000002718","volume":"111","author":"QD Zhu","year":"2025","unstructured":"Zhu QD, Song C, Zhao CY, Qiang HB, Liu RH, Gong CM, et al. Antibody-drug conjugates in lung cancer: scientific breakthroughs and future directions in clinical trials. Int J Surg. 2025;111(9):6465\u20138. https:\/\/doi.org\/10.1097\/js9.0000000000002718.","journal-title":"Int J Surg"},{"key":"1784_CR69","doi-asserted-by":"publisher","first-page":"103074","DOI":"10.1016\/j.ebiom.2020.103074","volume":"62","author":"Z Li","year":"2020","unstructured":"Li Z, Chen S, Feng W, Luo Y, Lai H, Li Q, et al. A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy. EBioMedicine. 2020;62:103074. https:\/\/doi.org\/10.1016\/j.ebiom.2020.103074.","journal-title":"EBioMedicine"},{"key":"1784_CR70","doi-asserted-by":"publisher","unstructured":"McGale J, Khurana S, Huang A, Roa T, Yeh R, Shirini D, et al. PET\/CT and SPECT\/CT Imaging of HER2-Positive Breast Cancer. J Clin Med. 2023;12(15). https:\/\/doi.org\/10.3390\/jcm12154882.","DOI":"10.3390\/jcm12154882"},{"issue":"11","key":"1784_CR71","doi-asserted-by":"publisher","first-page":"8612","DOI":"10.1097\/js9.0000000000002930","volume":"111","author":"R Duan","year":"2025","unstructured":"Duan R. Development of antibody-drug conjugates in gastric cancer: an overview of clinical trials from 2005 to 2025. Int J Surg. 2025;111(11):8612\u20135. https:\/\/doi.org\/10.1097\/js9.0000000000002930.","journal-title":"Int J Surg"},{"key":"1784_CR72","doi-asserted-by":"publisher","unstructured":"Bhatt A, Yone N, Lalla M, Jeon H, Cheng H. Molecular Diagnosis, Clinical Trial Representation, and Precision Medicine in Minority Patients with Oncogene-Driven Lung Cancer. Cancers (Basel). 2025;17(12). https:\/\/doi.org\/10.3390\/cancers17121950.","DOI":"10.3390\/cancers17121950"},{"issue":"1","key":"1784_CR73","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s13048-025-01845-6","volume":"18","author":"G Xie","year":"2025","unstructured":"Xie G, Chen G, Lv W, Tai W, Zhang B, Zhou X. Trophoblast cell surface antigen 2 (TROP2) from ascitic extracellular vesicles drives peritoneal metastasis of ovarian cancer by mesothelial-to-mesenchymal transition. J Ovarian Res. 2025;18(1):311. https:\/\/doi.org\/10.1186\/s13048-025-01845-6.","journal-title":"J Ovarian Res"},{"key":"1784_CR74","doi-asserted-by":"publisher","unstructured":"Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M, et al. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. J Clin Med. 2020;10(1). https:\/\/doi.org\/10.3390\/jcm10010088.","DOI":"10.3390\/jcm10010088"},{"key":"1784_CR75","doi-asserted-by":"publisher","first-page":"175883592210869","DOI":"10.1177\/17588359221086916","volume":"14","author":"LA Huppert","year":"2022","unstructured":"Huppert LA, Gumusay O, Rugo HS. Emerging treatment strategies for metastatic triple-negative breast cancer. Ther Adv Med Oncol. 2022;14:17588359221086916. https:\/\/doi.org\/10.1177\/17588359221086916.","journal-title":"Ther Adv Med Oncol"},{"issue":"10","key":"1784_CR76","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ajhp\/zxaf011","volume":"82","author":"JA Smith","year":"2025","unstructured":"Smith JA, Medina P, Miao M, Moore KN. A review of mirvetuximab soravtansine-gynx in folate receptor alpha-expressing platinum-resistant ovarian cancer. Am J Health Syst Pharm. 2025;82(10):522\u201336. https:\/\/doi.org\/10.1093\/ajhp\/zxaf011.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"1784_CR77","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-025-02281-0","volume":"10","author":"P Shu","year":"2025","unstructured":"Shu P, Li X, Zhou Q, Li G, Zhang K, Yuan L, et al. Multicenter phase 1\/2 study of onatasertib, a dual TORC1\/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors. Signal Transduct Target Ther. 2025;10(1):198. https:\/\/doi.org\/10.1038\/s41392-025-02281-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1784_CR78","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1021\/acs.jmedchem.4c00568","volume":"67","author":"KA Iyer","year":"2024","unstructured":"Iyer KA, Ivanov J, Tenchov R, Ralhan K, Rodriguez Y, Sasso JM, et al. Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis. J Med Chem. 2024;67(11):8519\u201344. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00568.","journal-title":"J Med Chem"},{"issue":"4","key":"1784_CR79","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40487-025-00379-7","volume":"13","author":"B Xie","year":"2025","unstructured":"Xie B, Chen C, Cai H, Wang L, Chen M, Liu J, et al. Application and Progress of Antibody-Drug Conjugates (ADCs) in the Treatment of Metastatic Triple-Negative Breast Cancer. Oncol Ther. 2025;13(4):919\u201337. https:\/\/doi.org\/10.1007\/s40487-025-00379-7.","journal-title":"Oncol Ther"},{"key":"1784_CR80","doi-asserted-by":"publisher","unstructured":"Lerchen HG, Stelte-Ludwig B, Heroult M, Zubov D, Gericke KM, Wong H, et al. Discovery of VIP236, an \u03b1v\u03b23-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid Tumors. Cancers (Basel). 2023;15(17). https:\/\/doi.org\/10.3390\/cancers15174381.","DOI":"10.3390\/cancers15174381"},{"key":"1784_CR81","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2147\/ijn.S290346","volume":"16","author":"Z Li","year":"2021","unstructured":"Li Z, Liu Y, Fang X, Shu Z. Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. Int J Nanomed. 2021;16:1631\u201361. https:\/\/doi.org\/10.2147\/ijn.S290346.","journal-title":"Int J Nanomed"},{"issue":"12","key":"1784_CR82","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","volume":"61","author":"D Waghray","year":"2018","unstructured":"Waghray D, Zhang Q. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. J Med Chem. 2018;61(12):5108\u201321. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01457.","journal-title":"J Med Chem"},{"key":"1784_CR83","doi-asserted-by":"publisher","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2020;25(20). https:\/\/doi.org\/10.3390\/molecules25204764.","DOI":"10.3390\/molecules25204764"},{"issue":"4","key":"1784_CR84","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12282-019-00949-4","volume":"26","author":"S Noda-Narita","year":"2019","unstructured":"Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, et al. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer. 2019;26(4):492\u20138. https:\/\/doi.org\/10.1007\/s12282-019-00949-4.","journal-title":"Breast Cancer"},{"key":"1784_CR85","doi-asserted-by":"publisher","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. 2023;24(11). https:\/\/doi.org\/10.3390\/ijms24119674.","DOI":"10.3390\/ijms24119674"},{"key":"1784_CR86","doi-asserted-by":"publisher","first-page":"667689","DOI":"10.3389\/fonc.2021.667689","volume":"11","author":"Z Bai","year":"2021","unstructured":"Bai Z, Zhou Q, Zhu H, Ye X, Wu P, Ma L. QTMP, a Novel Thiourea Polymer, Causes DNA Damage to Exert Anticancer Activity and Overcome Multidrug Resistance in Colorectal Cancer Cells. Front Oncol. 2021;11:667689. https:\/\/doi.org\/10.3389\/fonc.2021.667689.","journal-title":"Front Oncol"},{"key":"1784_CR87","doi-asserted-by":"publisher","unstructured":"Ferretti GDS, Quarti J, Dos Santos G, Rangel LP, Silva JL. Anticancer Therapeutic Strategies Targeting p53 Aggregation. Int J Mol Sci. 2022;23(19). https:\/\/doi.org\/10.3390\/ijms231911023.","DOI":"10.3390\/ijms231911023"},{"issue":"6","key":"1784_CR88","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1208\/s12248-025-01115-9","volume":"27","author":"RMN Khan","year":"2025","unstructured":"Khan RMN, Zeng Y, Lanihun AA, Arisa OT, Horner JL, Figg WD. Recent Advances in Bioanalytical Methods for Quantification and Pharmacokinetic Analyses of Antibody-Drug Conjugates. Aaps j. 2025;27(6):138. https:\/\/doi.org\/10.1208\/s12248-025-01115-9.","journal-title":"Aaps j"},{"issue":"1","key":"1784_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","volume":"13","author":"L Zhou","year":"2024","unstructured":"Zhou L, Lu Y, Liu W, Wang S, Wang L, Zheng P, et al. Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice. Exp Hematol Oncol. 2024;13(1):26. https:\/\/doi.org\/10.1186\/s40164-024-00493-8.","journal-title":"Exp Hematol Oncol"},{"key":"1784_CR90","doi-asserted-by":"publisher","unstructured":"Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2021;26(19). https:\/\/doi.org\/10.3390\/molecules26195847.","DOI":"10.3390\/molecules26195847"},{"issue":"1","key":"1784_CR91","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","volume":"14","author":"B Ziccheddu","year":"2024","unstructured":"Ziccheddu B, Giannotta C, D\u2019Agostino M, Bertuglia G, Saraci E, Oliva S, et al. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma. Blood Cancer J. 2024;14(1):117. https:\/\/doi.org\/10.1038\/s41408-024-01096-6.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1784_CR92","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","volume":"15","author":"S Li","year":"2025","unstructured":"Li S, Zhao X, Fu K, Zhu S, Pan C, Yang C, et al. Resistance to antibody-drug conjugates: A review. Acta Pharm Sin B. 2025;15(2):737\u201356. https:\/\/doi.org\/10.1016\/j.apsb.2024.12.036.","journal-title":"Acta Pharm Sin B"},{"key":"1784_CR93","doi-asserted-by":"publisher","first-page":"1451230","DOI":"10.3389\/fonc.2024.1451230","volume":"14","author":"L Yu","year":"2024","unstructured":"Yu L, Yang R, Long Z, Tao Q, Liu B. Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials. Front Oncol. 2024;14:1451230. https:\/\/doi.org\/10.3389\/fonc.2024.1451230.","journal-title":"Front Oncol"},{"issue":"23","key":"1784_CR94","doi-asserted-by":"publisher","first-page":"e71415","DOI":"10.1002\/cam4.71415","volume":"14","author":"S Lee","year":"2025","unstructured":"Lee S, Kahn AM, Rozenblit M, George MA, Naranjo Ortiz C, Lustberg MB. HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer. Cancer Med. 2025;14(23):e71415. https:\/\/doi.org\/10.1002\/cam4.71415.","journal-title":"Cancer Med"},{"issue":"1","key":"1784_CR95","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41698-022-00338-9","volume":"7","author":"N Coleman","year":"2023","unstructured":"Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: dawn of a new era? NPJ Precis Oncol. 2023;7(1):5. https:\/\/doi.org\/10.1038\/s41698-022-00338-9.","journal-title":"NPJ Precis Oncol"},{"issue":"9","key":"1784_CR96","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.leukres.2004.01.009","volume":"28","author":"PP Piccaluga","year":"2004","unstructured":"Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res. 2004;28(9):987\u201390. https:\/\/doi.org\/10.1016\/j.leukres.2004.01.009.","journal-title":"Leuk Res"},{"issue":"1","key":"1784_CR97","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-025-04863-9","volume":"96","author":"X Ji","year":"2026","unstructured":"Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, et al. Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. Cancer Chemother Pharmacol. 2026;96(1):15. https:\/\/doi.org\/10.1007\/s00280-025-04863-9.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1784_CR98","doi-asserted-by":"publisher","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers (Basel). 2023;15(3). https:\/\/doi.org\/10.3390\/cancers15030713.","DOI":"10.3390\/cancers15030713"},{"issue":"5","key":"1784_CR99","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00280-023-04516-9","volume":"91","author":"P Montesinos","year":"2023","unstructured":"Montesinos P, Kota V, Brandwein J, Bousset P, Benner RJ, Vandendries E, et al. A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed\/refractory CD33-positive acute myeloid leukemia. Cancer Chemother Pharmacol. 2023;91(5):441\u20136. https:\/\/doi.org\/10.1007\/s00280-023-04516-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1784_CR100","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1080\/19420862.2018.1517565","volume":"10","author":"DD Leipold","year":"2018","unstructured":"Leipold DD, Figueroa I, Masih S, Latifi B, Yip V, Shen BQ, et al. Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: An antibody-drug conjugate for the treatment of acute myeloid leukemia. MAbs. 2018;10(8):1312\u201321. https:\/\/doi.org\/10.1080\/19420862.2018.1517565.","journal-title":"MAbs"},{"key":"1784_CR101","doi-asserted-by":"publisher","unstructured":"Gottardi M, Simonetti G, Sperotto A, Nappi D, Ghelli Luserna di Ror\u00e0, Padella A et al. A,. Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. Cancers (Basel). 2021;13(18). https:\/\/doi.org\/10.3390\/cancers13184566","DOI":"10.3390\/cancers13184566"},{"key":"1784_CR102","doi-asserted-by":"publisher","unstructured":"Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired Resistance to Antibody-Drug Conjugates. Cancers (Basel). 2019;11(3). https:\/\/doi.org\/10.3390\/cancers11030394.","DOI":"10.3390\/cancers11030394"},{"issue":"9","key":"1784_CR103","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","volume":"106","author":"J Duell","year":"2021","unstructured":"Duell J, Maddocks KJ, Gonz\u00e1lez-Barca E, Jurczak W, Liberati AM, De Vos S, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417\u201326. https:\/\/doi.org\/10.3324\/haematol.2020.275958.","journal-title":"Haematologica"},{"key":"1784_CR104","doi-asserted-by":"publisher","first-page":"204062072198958","DOI":"10.1177\/2040620721989585","volume":"12","author":"L Sanchez","year":"2021","unstructured":"Sanchez L, Dardac A, Madduri D, Richard S, Richter J. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther Adv Hematol. 2021;12:2040620721989585. https:\/\/doi.org\/10.1177\/2040620721989585.","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"1784_CR105","doi-asserted-by":"publisher","first-page":"279","DOI":"10.6004\/jadpro.2021.12.3.12","volume":"12","author":"HD Finnes","year":"2021","unstructured":"Finnes HD. 2019\u20132020 Drug Updates in Hematologic Malignancies. J Adv Pract Oncol. 2021;12(3):279\u2013. https:\/\/doi.org\/10.6004\/jadpro.2021.12.3.12. \u200983.","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"1784_CR106","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther. 2022;7(1):39. https:\/\/doi.org\/10.1038\/s41392-021-00868-x.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"1784_CR107","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","volume":"34","author":"JM Lambert","year":"2017","unstructured":"Lambert JM, Morris CQ. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv Ther. 2017;34(5):1015\u201335. https:\/\/doi.org\/10.1007\/s12325-017-0519-6.","journal-title":"Adv Ther"},{"issue":"22","key":"1784_CR108","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1182\/bloodadvances.2025016949","volume":"9","author":"MV Mateos","year":"2025","unstructured":"Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, et al. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025;9(22):5708\u201319. https:\/\/doi.org\/10.1182\/bloodadvances.2025016949.","journal-title":"Blood Adv"},{"key":"1784_CR109","doi-asserted-by":"publisher","first-page":"3","DOI":"10.21037\/tbcr-23-48","volume":"5","author":"Q Wu","year":"2024","unstructured":"Wu Q, Xu L. Challenges in HER2-low breast cancer identification, detection, and treatment. Transl Breast Cancer Res. 2024;5:3. https:\/\/doi.org\/10.21037\/tbcr-23-48.","journal-title":"Transl Breast Cancer Res"},{"issue":"1","key":"1784_CR110","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41598-025-86504-y","volume":"15","author":"S Dong","year":"2025","unstructured":"Dong S, Wei C, Wang X, Yang X, Shen W, Li S, et al. A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer. Sci Rep. 2025;15(1):2232. https:\/\/doi.org\/10.1038\/s41598-025-86504-y.","journal-title":"Sci Rep"},{"issue":"5","key":"1784_CR111","doi-asserted-by":"publisher","first-page":"519","DOI":"10.4048\/jbc.2023.26.e38","volume":"26","author":"VA de Weger","year":"2023","unstructured":"de Weger VA, Schutte T, Konings I. Menke-van der Houven van Oordt CW. Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report. J Breast Cancer. 2023;26(5):519\u201323. https:\/\/doi.org\/10.4048\/jbc.2023.26.e38.","journal-title":"J Breast Cancer"},{"issue":"null","key":"1784_CR112","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.2147\/DDDT.S508773","volume":"19","author":"D Liao","year":"2025","unstructured":"Liao D, Zhang J, Yan T, Chen Y, Fu Y, Xie N, et al. A Systematic Review of Mechanisms, Incidence, and Management of Trastuzumab Deruxtecan Induced ILD\/Pneumonitis in Solid Tumors. Drug Des Devel Ther. 2025;19(null):1655\u201368. https:\/\/doi.org\/10.2147\/DDDT.S508773.","journal-title":"Drug Des Devel Ther"},{"issue":"17","key":"1784_CR113","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.7150\/jca.86746","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu F, Yin G, Xue S, Rehman FU, Liao D, Pan Y. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study. J Cancer. 2023;14(17):3275\u201384. https:\/\/doi.org\/10.7150\/jca.86746.","journal-title":"J Cancer"},{"key":"1784_CR114","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.eclinm.2025.103160","volume":"82","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Li Y, Zhu C, Dong Q, Zhang Y, Liu Z, et al. Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance study. EClinicalMedicine. 2025;82:103160. https:\/\/doi.org\/10.1016\/j.eclinm.2025.103160.","journal-title":"EClinicalMedicine"},{"key":"1784_CR115","doi-asserted-by":"publisher","first-page":"1516419","DOI":"10.3389\/fimmu.2025.1516419","volume":"16","author":"R Long","year":"2025","unstructured":"Long R, Zuo H, Tang G, Zhang C, Yue X, Yang J, et al. Antibody-drug conjugates in cancer therapy: applications and future advances. Front Immunol. 2025;16:1516419. https:\/\/doi.org\/10.3389\/fimmu.2025.1516419.","journal-title":"Front Immunol"},{"issue":"6","key":"1784_CR116","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"1784_CR117","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.3892\/ol.2018.9447","volume":"16","author":"X Fu","year":"2018","unstructured":"Fu X, Shang Y, Zhang L, Li L, Li X, Wang X, et al. Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review. Oncol Lett. 2018;16(5):6624\u201332. https:\/\/doi.org\/10.3892\/ol.2018.9447.","journal-title":"Oncol Lett"},{"issue":"1","key":"1784_CR118","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105. https:\/\/doi.org\/10.1186\/s13045-024-01625-7.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"1784_CR119","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/acs.bioconjchem.5c00070","volume":"36","author":"PA Birikorang","year":"2025","unstructured":"Birikorang PA, Menendez DM, Edinger R, Kohanbash G, Edwards WB. Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody. Bioconjug Chem. 2025;36(6):1208\u201317. https:\/\/doi.org\/10.1021\/acs.bioconjchem.5c00070.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"1784_CR120","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen M, Yu A, Park Y, Calarese D, Gerber HP, Yin G. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs. 2025;17(1):2498162. https:\/\/doi.org\/10.1080\/19420862.2025.2498162.","journal-title":"MAbs"},{"key":"1784_CR121","doi-asserted-by":"publisher","unstructured":"McKertish CM, Kayser VA, Novel Dual-Payload. ADC for the Treatment of HER2\u2009+\u2009Breast and Colon Cancer. Pharmaceutics. 2023;15(8). https:\/\/doi.org\/10.3390\/pharmaceutics15082020.","DOI":"10.3390\/pharmaceutics15082020"},{"issue":"8","key":"1784_CR122","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"1784_CR123","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1\u2009+\u20091>2. Acta Pharm Sin B. 2024;14(5):1965\u201386. https:\/\/doi.org\/10.1016\/j.apsb.2024.01.009.","journal-title":"Acta Pharm Sin B"},{"issue":"75","key":"1784_CR124","doi-asserted-by":"publisher","first-page":"34103","DOI":"10.18632\/oncotarget.26135","volume":"9","author":"M Quanz","year":"2018","unstructured":"Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, et al. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models. Oncotarget. 2018;9(75):34103\u201321. https:\/\/doi.org\/10.18632\/oncotarget.26135.","journal-title":"Oncotarget"},{"key":"1784_CR125","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1186\/s12885-015-1772-1","volume":"15","author":"S Kan","year":"2015","unstructured":"Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, et al. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells. BMC Cancer. 2015;15:726. https:\/\/doi.org\/10.1186\/s12885-015-1772-1.","journal-title":"BMC Cancer"},{"issue":"1","key":"1784_CR126","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12885-024-12652-5","volume":"24","author":"W Zhou","year":"2024","unstructured":"Zhou W, Xu Z, Liu S, Lou X, Liu P, Xie H, et al. Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022. BMC Cancer. 2024;24(1):898. https:\/\/doi.org\/10.1186\/s12885-024-12652-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"1784_CR127","first-page":"159","volume":"50","author":"H Kalofonos","year":"1990","unstructured":"Kalofonos H, Rowlinson G, Epenetos AA. Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res. 1990;50(1):159\u201363.","journal-title":"Cancer Res"},{"issue":"13","key":"1784_CR128","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1158\/1078-0432.Ccr-18-2851","volume":"25","author":"PK Stumpf","year":"2019","unstructured":"Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, et al. Combination of Trastuzumab Emtansine and Stereotactic Radiosurgery Results in High Rates of Clinically Significant Radionecrosis and Dysregulation of Aquaporin-4. Clin Cancer Res. 2019;25(13):3946\u201353. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2851.","journal-title":"Clin Cancer Res"},{"key":"1784_CR129","doi-asserted-by":"publisher","unstructured":"Debbi K, Grellier N, Loganadane G, Boukhobza C, Mah\u00e9 M, Cherif MA, et al. Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. Cancers (Basel). 2023;15(8). https:\/\/doi.org\/10.3390\/cancers15082278.","DOI":"10.3390\/cancers15082278"},{"issue":"3","key":"1784_CR130","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.Can-17-1638","volume":"78","author":"C Cilliers","year":"2018","unstructured":"Cilliers C, Menezes B, Nessler I, Linderman J, Thurber GM. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res. 2018;78(3):758\u201368. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1638.","journal-title":"Cancer Res"},{"issue":"12","key":"1784_CR131","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","volume":"18","author":"JF Ponte","year":"2016","unstructured":"Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, et al. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 2016;18(12):775\u201384. https:\/\/doi.org\/10.1016\/j.neo.2016.11.002.","journal-title":"Neoplasia"},{"issue":"5","key":"1784_CR132","doi-asserted-by":"publisher","first-page":"100260","DOI":"10.1016\/j.esmoop.2021.100260","volume":"6","author":"M Riudavets","year":"2021","unstructured":"Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6(5):100260. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100260.","journal-title":"ESMO Open"},{"issue":"4","key":"1784_CR133","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","volume":"9","author":"J Fuentes-Antr\u00e1s","year":"2023","unstructured":"Fuentes-Antr\u00e1s J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends Cancer. 2023;9(4):339\u201354. https:\/\/doi.org\/10.1016\/j.trecan.2023.01.003.","journal-title":"Trends Cancer"},{"issue":"8","key":"1784_CR134","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41589-025-01950-z","volume":"21","author":"A Croitoru","year":"2025","unstructured":"Croitoru A, Orr AA, MacKerell AD. Jr. Harnessing computational technologies to facilitate antibody-drug conjugate development. Nat Chem Biol. 2025;21(8):1138\u201347. https:\/\/doi.org\/10.1038\/s41589-025-01950-z.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"1784_CR135","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","volume":"9","author":"Y Lu","year":"2025","unstructured":"Lu Y, Huang W, Li Y, Xu Y, Wei Q, Sha C, et al. Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology. NPJ Precis Oncol. 2025;9(1):374. https:\/\/doi.org\/10.1038\/s41698-025-01159-2.","journal-title":"NPJ Precis Oncol"},{"key":"1784_CR136","doi-asserted-by":"publisher","first-page":"1553853","DOI":"10.3389\/fphar.2025.1553853","volume":"16","author":"DE Zhang","year":"2025","unstructured":"Zhang DE, He T, Shi T, Huang K, Peng A. Trends in the research and development of peptide drug conjugates: artificial intelligence aided design. Front Pharmacol. 2025;16:1553853. https:\/\/doi.org\/10.3389\/fphar.2025.1553853.","journal-title":"Front Pharmacol"},{"issue":"42","key":"1784_CR137","doi-asserted-by":"publisher","first-page":"e10239","DOI":"10.1002\/adma.202510239","volume":"37","author":"H Bae","year":"2025","unstructured":"Bae H, Ji H, Konstantinov K, Sluyter R, Ariga K, Kim YH, et al. Artificial Intelligence-Driven Nanoarchitectonics for Smart Targeted Drug Delivery. Adv Mater. 2025;37(42):e10239. https:\/\/doi.org\/10.1002\/adma.202510239.","journal-title":"Adv Mater"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01784-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01784-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01784-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:24:55Z","timestamp":1777278295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01784-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01784-5","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review does not involve human participants, human data, or human tissue.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable. No individual patient data are included in this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44"}}